Barbexaclone

Barbexaclone (Maliasin) is a salt compound of phenobarbital and levopropylhexedrine.[1] It was introduced in 1983. It has been reported to be as effective as phenobarbital but better tolerated; however, as of 2004, these "promising results"[2] had not yet been confirmed nor denied in controlled trials.

Barbexaclone
Combination of
PhenobarbitalBarbiturate
LevopropylhexedrineStimulant (sympathomimetic)
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
CompTox Dashboard (EPA)
ECHA InfoCard100.022.278
 NY (what is this?)  (verify)

Potency

100 mg of barbexaclone is equivalent to 60 mg of phenobarbital.[1]

References
  1. Simon Shorvon; Emilio Perucca; Jerome Engel, Jr. (23 September 2015). The Treatment of Epilepsy. Wiley. pp. 1706–1707. ISBN 978-1-118-93699-3.
  2. Salles Barbosa, MF (September 1978). "[Barbexaclone in the treatment of cerebral dysrhythmia]". Arquivos de Neuro-Psiquiatria. 36 (3): 245–9. doi:10.1590/s0004-282x1978000300009. PMID 28716.
Bibliography
  • The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. p. 472. ISBN 0-632-06046-8


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.